How do you forecast a drug discovery business?

Financial models are particularly important for drug discovery and biotechnology companies, mainly because they have long R&D cycles and large capital requirements at every stage.

This means you need robust long-term financial planning and sufficiently justified valuations at each fundraising point, backed by both solid forecasts and other value drivers.

This sector has some interesting aspects to it.

Key takeaways are below;

💧 Funding is the lifeblood of early-stage biotechs. Without a coherent capital strategy, even the strongest science can stall. Survival depends on the ability to raise funds.

🔬 Biotech is capital-intensive, long-cycle, and high-risk. Plan for multiple large fundraises, underpinned by a robust long-term financial model / forecast.

📊 Financial strategy has a large impact on your exit value. 95% of life science projects fail to meet their authorised cost schedule. Accurate cash requirements at each fundraising point are critical, especially at early stages where valuation errors are most costly to equity dilution.

📅 Scenario planning is largely driven by timing. Bear case scenarios should model delays to clinical trials and revenue timelines. And always build in a contingency buffer (c.15%) to account for the unexpected.

🤝 Investors back teams who command both the biology and the capital plan. A strong model and a confident grip on the numbers improves terms and accelerates fundraising.

🎯 Efficient resource allocation matters. Avoid spreading capital thinly. Focus money on the milestones that genuinely create value.

🔄 Strategic flexibility extends your runway. Partnerships, grants, and staged raises can reduce dilution and keep optionality open.

And finally, valuation is an art, not a science.

"Price is what you pay; value is what you get."

Value is inherently subjective in life sciences. A compelling story backed by strong numbers is essential, but don't underestimate the strategic drivers: patents, clinical trial results, market news, team quality, etc too.